For citations:
Avxentyev N.A., Lubennikova E.V., Frolov M.Yu. Pharmacoeconomic analysis of using cyclin-dependent kinase 4 and 6 inhibitors in the first line treatment of HR-positive HER2-negative advanced breast cancer. FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology. 2019;12(4):279-290. (In Russ.) https://doi.org/10.17749/2070-4909.2019.12.4.279-290
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Email this article 